Combining stem cells and exon skipping strategy to treat muscular dystrophy
Meregalli M, Farini A, Torrente Y.
Stem Cell Laboratory, Department of Neurological Sciences,
University of Milan, Padiglione Ponti, Fondazione IRCCS,
Ospedale Policlinico, via Francesco Sforza 35,
20122 Milan, Italy.
Expert Opin Biol Ther. 2008 Aug;8(8):1051-61.


BACKGROUND: Muscular dystrophies are characterized by primary wasting of skeletal muscle. Mutations in the dystrophin gene cause hereditary muscular diseases such as Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD), the most severe form. Characterization of the dystrophin gene and evidence that different types of adult stem cells are capable of muscle regeneration has lead to the development of potential gene therapy and stem cell treatments for DMD. OBJECTIVES: The main goal is to combine gene modification strategies with cell-mediated therapies. This approach could permit autologous transplantation of cells, minimizing the risk of implant rejection. RESULTS/CONCLUSION: The combination of gene and stem cell approaches seems to be most promising, particularly intra-arterial injections of the patient's own stem cells transduced by antisense oligonucleotide technology. This approach should offer the chance to distribute the autologous corrected stem cells to the whole body musculature providing a clinical benefit for dystrophic patients.
Heritable HACs
Private eugenics
'Designer babies'
Personal genomics
Genetic enhancement
Ashkenazi intelligence
'Liberal eugenics' (PDF)
Eugenics before Galton
Scandanavian eugenics
The literature of eugenics
Genetic moral enhancement
Duchenne muscular dystrophy (DMD)

and further reading

BLTC Research
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World